Abstract | PURPOSE: METHODS: A cohort study was conducted using the UK Clinical Practice Research Datalink. Patients were aged 40+ and had COPD (n = 32 693). Current users of ICS were stratified by relative and absolute eosinophil counts to determine the risk of outcomes with blood eosiniphilia using Cox regression analysis. RESULTS: Among COPD patients, current use of ICS was not associated with a reduced risk of acute COPD exacerbations, COPD-related hospitalisations/accident and emergency visits, and all-cause mortality. Stratification of ICS use by absolute or relative eosinophil counts did not result in significant differences in risk of COPD exacerbations or hospitalisations/accident and emergency visits. However, all-cause mortality was reduced by 12% to 24% among patients with eosinophilia. CONCLUSIONS:
COPD-related acute exacerbations or hospitalisations/accident and emergency visits were not reduced with eosinophilia among users of ICS with COPD. However, all-cause mortality was reduced by 12% to 24%. These findings are potentially important and require further evaluation in prospective studies.
|
Authors | Olorunfemi A Oshagbemi, Frits M E Franssen, Dionne C W Braeken, Yvonne Henskens, Emiel F M Wouters, Anke-Hilse Maitland-van der Zee, Andrea M Burden, Frank de Vries |
Journal | Pharmacoepidemiology and drug safety
(Pharmacoepidemiol Drug Saf)
Vol. 27
Issue 11
Pg. 1191-1199
(11 2018)
ISSN: 1099-1557 [Electronic] England |
PMID | 30264901
(Publication Type: Journal Article)
|
Copyright | © 2018 The Authors. Pharmacoepidemiology & Drug Safety Published by John Wiley & Sons Ltd. |
Chemical References |
|
Topics |
- Administration, Inhalation
- Adult
- Aged
- Aged, 80 and over
- Disease Progression
- Dose-Response Relationship, Drug
- Emergency Service, Hospital
(statistics & numerical data)
- Eosinophilia
(blood, chemically induced, epidemiology)
- Female
- Follow-Up Studies
- Glucocorticoids
(administration & dosage, adverse effects)
- Hospitalization
(statistics & numerical data)
- Humans
- Male
- Middle Aged
- Prospective Studies
- Pulmonary Disease, Chronic Obstructive
(blood, drug therapy, mortality, pathology)
- Reproducibility of Results
- Risk Assessment
- United Kingdom
(epidemiology)
|